Emergent BioSolutions (EBS) Misses Q2 EPS by 1c
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $8.01 +2.04%
Revenue Growth %: +32.0%
Financial Fact:
Weighted-average number of shares - diluted: 49.44M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Revenue Growth %: +32.0%
Financial Fact:
Weighted-average number of shares - diluted: 49.44M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q2 EPS of ($0.18), $0.01 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $101.5 million versus the consensus estimate of $111.2 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- After-Hours Stock Movers: FDX, CBRS, NKE
- Nike names former Pfizer CFO David Denton as new finance chief
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
